Abstract
BackgroundBispecific T-cell engagers (BTEs) are novel agents used to treat hematological malignancies. Early trials were underpowered to define cardiovascular adverse events (CVAE) and no large-scale studies systematically examined the CVAEs...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have